Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 38 FP4 | DOI: 10.1530/endoabs.38.FP4

SFEBES2015 Featured Posters (1) (12 abstracts)

GLP-1 reduces cerebrospinal fluid secretion and intracranial pressure: a novel treatment for idiopathic intracranial hypertension?

Hannah Botfield 1 , Maria Uldall 2 , James Mitchell 1 , Ana Maria Gonzalez 1 , Rigmor Jensen 2 & Alexandra Sinclair 1,

1Institute of Metabolism and Systems Research, University of Birmingham, Centre for Endocrinology, Diabetes and Metabolism Birmingham Health Partners, Birmingham, UK, Birmingham, West Midlands, UK; 2University of Copenhagen, Glostrup, Denmark; 3University Hospitals Birmingham, NHS Trust, Queen Elizabeth Hospital, Birmingham, West Midlands, UK.

Background: Idiopathic intracranial hypertension (IIH) predominantly affects obese women of childbearing age. IIH is characterised by increased intracranial pressure (ICP) which results in visual loss and disabling headaches. ICP dis-regulation results from imbalance of cerebrospinal fluid (CSF) production rate (at the choroid plexus epithelial cells) and drainage. Treatments for IIH are limited but weight loss is established as disease modifying.

Glucagon like peptide-1 (GLP-1), an incretin with weight modifying properties, has been shown to have a natriuretic effect in the kidney through inhibition of the Na+H+ exchanger in proximal tubule cells. CSF secretion is controlled by ion channels and pumps akin to an inverted renal proximal tubule. The choroid plexus (CP) expresses GLP-1 receptor (GLP-1R). Therefore, we hypothesise that GLP-1 modulates CSF secretion at the choroid plexus and reduces ICP.

Results: GLP-1 receptor mRNA (QPCR) and protein (WB) were detected in the rat CP. Immunohistochemical analysis of CP explants showed that GLP-1R localised to the cytoplasm and apical surface of the epithelial cells. After Exendin-4 (GLP-1R agonist) treatment GLP-1R immunoreactivity was translocated to the apical cell surface. GLP-1R mRNA and protein levels were also increased. Evaluation of the downstream signalling pathway on primary CP epithelial cells identified a twofold increase in cAMP after Exendin-4 treatment (P<0.01). Exendin-4 also significantly reduced the activity of Na+K+ ATPase, a marker of CSF secretion (39.3±9.4% of control; P<0.05). In vivo ICP recording in adult rats (n=6) demonstrated that Exendin-4 significantly reduced ICP (58.3±5.0%, P<0.0001).

Conclusions: We have identified a novel GLP-1 signalling pathway in the CP. We demonstrate that treatment with a GLP-1 agonist significantly reduces CSF secretion in vitro and ICP in rats. GLP-1 therapy may represent a novel therapeutic avenue for conditions of raised ICP such as IIH and may have additional long term advantages of weight reduction.

Volume 38

Society for Endocrinology BES 2015

Edinburgh, UK
02 Nov 2015 - 04 Nov 2015

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.